Zacks Investment Research Lowers TERUMO CORP/ADR (OTCMKTS:TRUMY) to Hold

TERUMO CORP/ADR (OTCMKTS:TRUMY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Terumo Corporation is engaged in the manufacture and sales of medical products and equipment. The products offered by the Company covers General Hospital Products, Cardiac & Vascular Products, Blood Transfusion Products and Consumer Healthcare Products. General hospital products offered by it include Disposable Medical Equipment, Medical Electronic Products, Diabetes Care Products, CAPD Systems and Pharmaceuticals; Cardiac & Vascular Products include Interventional Systems, Cardiovascular Systems and Artificial Vascular Grafts. Terumo’s Blood Transfusion products include blood bags, blood filter, filter in line, blood administration sets and apheresis, while consumer healthcare products include ear thermometer, electronic thermometer, basal body thermometer, electronic sphygmomanometer, urine test strip and leg compression stockings. Terumo Corporation is headquartered in Tokyo, Japan. “

Separately, Jefferies Financial Group downgraded TERUMO CORP/ADR from a “buy” rating to a “hold” rating in a research note on Wednesday, July 22nd.

Shares of OTCMKTS:TRUMY traded up $0.30 on Wednesday, hitting $40.33. The company’s stock had a trading volume of 5,516 shares, compared to its average volume of 18,015. TERUMO CORP/ADR has a 12 month low of $25.80 and a 12 month high of $42.16. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.48 and a current ratio of 2.17. The company has a market capitalization of $30.63 billion, a price-to-earnings ratio of 39.16 and a beta of 0.28. The stock’s 50-day moving average is $40.16 and its two-hundred day moving average is $36.65.

About TERUMO CORP/ADR

Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems.

Further Reading: How is a management fee different from a performance fee?

Get a free copy of the Zacks research report on TERUMO CORP/ADR (TRUMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TERUMO CORP/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TERUMO CORP/ADR and related companies with MarketBeat.com's FREE daily email newsletter.